Tumor budding to investigate local invasion, metastasis and prognosis in temporal bone squamous cell carcinoma.


Journal

Pathology, research and practice
ISSN: 1618-0631
Titre abrégé: Pathol Res Pract
Pays: Germany
ID NLM: 7806109

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 13 10 2021
revised: 22 11 2021
accepted: 25 11 2021
pubmed: 26 12 2021
medline: 25 3 2022
entrez: 25 12 2021
Statut: ppublish

Résumé

Few studies have tried to go beyond the conventional clinic-pathological prognostic factors investigating the molecular markers involved in the biology of temporal bone squamous cell carcinoma (TBSSC). Tumor budding represents a very aggressive subpopulation of cancer cells and demonstrates the heterogeneity of cancer cells residing in different locations within tumors. The main aim of this exploratory study was to investigate the role of tumor budding in primary TBSCC prognosis. We also analyzed the association between TBSCC tumor budding and: (i) loco-regional aggressiveness evaluated according to the revised Pittsburgh staging system, (ii) tumor infiltrating lymphocytes, lymphovascular invasion (LVSI), perineural invasion, pattern of invasion, and type of stroma. Thirty-two TBSCCs treated surgically were considered. The three-tier grading system recommended by the International Tumor Budding Consensus Conference was used first on TBSCC. Advanced (T3-4) TBSCC was related with high risk intra-tumoral budding (ITB) at two-tier risk grading (p = 0.0361). N + status was associated with intermediate/high budding (Bd2-3) at three-tier risk grading for peri-tumoral budding (PTB) (p = 0.0382). Disease-free survival (DFS) was related with T-stage (p = 0.0406), N-status (p < 0.0001), PTB two-tier risk grading (p = 0.0463), LVSI (p < 0.0001). Overall survival (OS) was associated with N-status (p = 0.0167), PTB absolute count (p = 0.0341), PTB three-tier risk grading (p = 0.0359), PTB two-tier risk grading (p = 0.0132), and LVSI (p = 0.0004). At the multivariate analysis, DFS was related with N-status (p = 0.0147) and LVSI (p < 0.0001), while OS resulted associated only with LVSI (p = 0.0144). Our preliminary findings suggest that tumor budding in TBSCC, regardless of its localization (the main tumor body [ITB] or invasive front [PTB]) may be a reliable predictor of neck lymph node metastasis and poor prognosis. Tumor budding and LVI could be predictive markers for precise treatment in TBSCC. Further investigations on larger prospective series should be designed to confirm this evidence both in post-operative specimens and in preoperative biopsies.

Sections du résumé

BACKGROUND BACKGROUND
Few studies have tried to go beyond the conventional clinic-pathological prognostic factors investigating the molecular markers involved in the biology of temporal bone squamous cell carcinoma (TBSSC). Tumor budding represents a very aggressive subpopulation of cancer cells and demonstrates the heterogeneity of cancer cells residing in different locations within tumors. The main aim of this exploratory study was to investigate the role of tumor budding in primary TBSCC prognosis. We also analyzed the association between TBSCC tumor budding and: (i) loco-regional aggressiveness evaluated according to the revised Pittsburgh staging system, (ii) tumor infiltrating lymphocytes, lymphovascular invasion (LVSI), perineural invasion, pattern of invasion, and type of stroma.
METHODS METHODS
Thirty-two TBSCCs treated surgically were considered. The three-tier grading system recommended by the International Tumor Budding Consensus Conference was used first on TBSCC.
RESULTS RESULTS
Advanced (T3-4) TBSCC was related with high risk intra-tumoral budding (ITB) at two-tier risk grading (p = 0.0361). N + status was associated with intermediate/high budding (Bd2-3) at three-tier risk grading for peri-tumoral budding (PTB) (p = 0.0382). Disease-free survival (DFS) was related with T-stage (p = 0.0406), N-status (p < 0.0001), PTB two-tier risk grading (p = 0.0463), LVSI (p < 0.0001). Overall survival (OS) was associated with N-status (p = 0.0167), PTB absolute count (p = 0.0341), PTB three-tier risk grading (p = 0.0359), PTB two-tier risk grading (p = 0.0132), and LVSI (p = 0.0004). At the multivariate analysis, DFS was related with N-status (p = 0.0147) and LVSI (p < 0.0001), while OS resulted associated only with LVSI (p = 0.0144).
CONCLUSIONS CONCLUSIONS
Our preliminary findings suggest that tumor budding in TBSCC, regardless of its localization (the main tumor body [ITB] or invasive front [PTB]) may be a reliable predictor of neck lymph node metastasis and poor prognosis. Tumor budding and LVI could be predictive markers for precise treatment in TBSCC. Further investigations on larger prospective series should be designed to confirm this evidence both in post-operative specimens and in preoperative biopsies.

Identifiants

pubmed: 34953406
pii: S0344-0338(21)00380-0
doi: 10.1016/j.prp.2021.153719
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

153719

Informations de copyright

Copyright © 2021 Elsevier GmbH. All rights reserved.

Auteurs

Lara Alessandrini (L)

Department of Medicine-DIMED, University of Padova, Padova, Italy.

Elisabetta Zanoletti (E)

Department of Neuroscience-DNS, Otolaryngology Section, University of Padova, Padova, Italy.

Diego Cazzador (D)

Department of Neuroscience-DNS, Otolaryngology Section, University of Padova, Padova, Italy.

Marta Sbaraglia (M)

Department of Medicine-DIMED, University of Padova, Padova, Italy.

Leonardo Franz (L)

Department of Neuroscience-DNS, Otolaryngology Section, University of Padova, Padova, Italy; Department of Otolaryngology-Head and Neck Surgery, University of Toronto, Toronto, ON, Canada.

Giulia Tealdo (G)

Department of Neuroscience-DNS, Otolaryngology Section, University of Padova, Padova, Italy.

Anna Chiara Frigo (AC)

Department of Cardiac-Thoracic-Vascular Sciences and Public Health, Padova University, Padova, Italy.

Stella Blandamura (S)

Department of Medicine-DIMED, University of Padova, Padova, Italy.

Piero Nicolai (P)

Department of Neuroscience-DNS, Otolaryngology Section, University of Padova, Padova, Italy.

Antonio Mazzoni (A)

Department of Neuroscience-DNS, Otolaryngology Section, University of Padova, Padova, Italy.

Gino Marioni (G)

Department of Neuroscience-DNS, Otolaryngology Section, University of Padova, Padova, Italy. Electronic address: gino.marioni@unipd.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH